Automated insulin delivery
Automated insulin delivery has been studied in 4 papers since 2025: 2 trials in people, 2 reviews; 2 in the past year. The newest paper, Jul 30, 2026: “Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study”.
4 papers study it4 findingsUpdated
See all 4 papers on automated insulin delivery
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“AHCL therapy was associated with a lower HFS-II score than standard treatment (adjusted mean difference -18.9; 95% CI: -32.4 to -5.4; nominal p = 0.008)”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Medtronic and 3 more
- 4 of 4 findings with company ties
- Human trial2
Studies in people
1 study gave automated insulin delivery to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases Hypoglycemia Fear Survey-IIadjusted mean difference -18.9; 95% CI: -32.4 to -5.4 up: Increases 6-minute walk distance92.6 m; 95% CI: 36.8 to 148.3 down: Decreases Timed Up-and-Go-2.27 s; 95% CI: -4.28 to -0.27 | Randomized trial12 months | 29 peopleBoth≥ 65 yearsOlder adults; in adults aged ≥ 65 years with type 1 diabetes | Diabetes, obesity & metabolism, Jul 30, 2026 |
What did studies of automated insulin delivery find?
4Studies of automated insulin delivery measured 4 outcomes, among them gait speed, Timed Up-and-Go and 6-minute walk distance.
Gait speed
no changein humans1
1 study
Gait speed
no changein humans1
Automated insulin delivery showed no clear effect on gait speed in adults aged ≥ 65 years with type 1 diabetes, sex-adjusted (0.27 m/s; 95% CI: -0.05 to 0.59).
“not for gait speed (0.27 m/s; 95% CI: -0.05 to 0.59; p = 0.099)”
Human trialin adults aged ≥ 65 years with type 1 diabetes, sex-adjustedMiniMed 780G system12 monthsn = 29
Diabetes, obesity & metabolism
Timed Up-and-Go
downin humans1
1 study
Timed Up-and-Go
downin humans1
Automated insulin delivery decreases Timed Up-and-Go in adults aged ≥ 65 years with type 1 diabetes, sex-adjusted (-2.27 s; 95% CI: -4.28 to -0.27).
“Timed Up and Go performance (-2.27 s; 95% CI: -4.28 to -0.27; p = 0.028)”
Human trialin adults aged ≥ 65 years with type 1 diabetes, sex-adjustedMiniMed 780G system12 monthsn = 29
Diabetes, obesity & metabolism
6-minute walk distance
upin humans1
1 study
6-minute walk distance
upin humans1
Automated insulin delivery increases 6-minute walk distance in adults aged ≥ 65 years with type 1 diabetes, sex-adjusted (92.6 m; 95% CI: 36.8 to 148.3).
“between-group differences remained statistically significant for 6-min walk distance (92.6 m; 95% CI: 36.8 to 148.3; p = 0.002)”
Human trialin adults aged ≥ 65 years with type 1 diabetes, sex-adjustedMiniMed 780G system12 monthsn = 29
Diabetes, obesity & metabolism
Hypoglycemia Fear Survey-II
downin humans1
1 study
Hypoglycemia Fear Survey-II
downin humans1
Automated insulin delivery decreases Hypoglycemia Fear Survey-II in adults aged ≥ 65 years with type 1 diabetes (adjusted mean difference -18.9; 95% CI: -32.4 to -5.4).
“AHCL therapy was associated with a lower HFS-II score than standard treatment (adjusted mean difference -18.9; 95% CI: -32.4 to -5.4; nominal p = 0.008)”
Human trialin adults aged ≥ 65 years with type 1 diabetesMiniMed 780G system12 monthsn = 29
Diabetes, obesity & metabolism
Funding
3 grants since 2021National Heart, Lung, and Blood Institute$931KNational Institute of Diabetes and Digestive and Kidney Diseases$1.3M